Abstract
TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers and specific genomic alterations. Results in a cohort of pts with LC and ERBB2 mut or amp treated with P+T are reported.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have